Insights provides context and perspective about key pharmacy trends and issues

Drug Pipeline
Promising Treatments for Alopecia Areata in the Pipeline
New Treatments for Alopecia Areata on the Horizon More
Briefing
Drug Pipeline
What's Next for Hemophilia Treatments?
What's Next for Hemophilia Therapy and New Treatment Options? More
Briefing
Drug Pipeline
Keeping an Eye on the Drug Pipeline
New Drugs for Ophthalmic Disorders on the Horizon More
Briefing
Drug Pipeline
Anticipating a Breakthrough Therapy for Type 1 Diabetes
Teplizumab: Potential Breakthrough Therapy for Type 1 Diabetes More
Briefing
Drug Pipeline
A Q2 2022 Look at Projected Gene Therapies and Approval Timelines
A Q2 2022 Look at Projected Gene Therapies and FDA Approval Timelines More
Briefing
Drug Pipeline
Treatment Options Expand in Robust Gene Therapy Pipeline
New Gene Therapies for Sickle Cell Disease, Hemophilia on the Horizon More
Briefing
Drug Pipeline
More Treatments, Costs for Patients with Inflammatory Bowel Disease
As more treatments for inflammatory bowel disease are approved, payors can counter cost increases with comprehensive utilization management. More
Briefing
Drug Pipeline
Expanding Therapies, Indications and Implications for Payors
2022 Marketplace Outlook: Expanding Therapies, Indications and Implications for Payors More
Briefing
Drug Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline More
Briefing
Speciality Pharmacy Pipeline Drugs to Watch | Q4 2021 - Q1 2022
Drug Pipeline
Speciality Pharmacy Pipeline Drugs to Watch | Q4 2021 - Q1 2022
Key drugs to watch for in the specialty pharmacy pipeline Q4 2021 - Q1 2022 More
Specialty Report